KRAS and colorectal carcinoma: Moreover, PRMT5 inhibition resulted in a further decrease in cell viability, as well as a further increase in apoptosis and G2 phase cell cycle arrest in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells.